In summary, our study supports targeting Arp2/3 complex subunits as a novel anticancer strategy, highlights the prognostic and diagnostic value of ARPC1A across cancers, and emphasizes the connections between ARPC1A, oxidative phosphorylation, and tumor immunity. This evidence concerns the gene ARPC1A and cancer.